NR-022 Ingredient Atlas entry · Amino acid

L-tyrosine

An amino acid in protein foods, also sold as N-acetyl-L-tyrosine (NALT)

An amino acid found in protein foods such as cheese, meat, fish and beans, and studied mostly for thinking and memory under stress, such as cold, heat or a night without sleep. Here is every study in people we could find, sorted, and the trials that are free online read in full.

  • Found in: cheese, meat, fish and beans
  • Often dosed by body weight
  • Often a single dose
Wheels of Parmigiano Reggiano cheese ageing on wooden shelves
Wheels of Parmigiano Reggiano cheese ageing on wooden shelves. Photo by Gilles Desjardins, CC BY-SA 4.0, via Wikimedia Commons
The research map

From every paper to the studies that matter

Most papers on tyrosine are about its role in the body, not about taking it. The studies in people are mostly of three kinds. Many give one large dose before a hard task. Many older ones are tyrosine load tests, which measured how the body clears a big dose, often in thyroid or liver disease. Smaller groups look at inherited conditions such as PKU, and only a few last a week or more.

  1. 16,484 papers mention tyrosine.Every record in PubMed, all years
  2. 356 are about people.The rest: 7,502 lab and animal studies, 485 reviews, 8,141 on chemistry, farming and more
  3. 135 give L-tyrosine or NALT on its own.43 more test it inside a blend, often with other amino acids
  4. 61 are randomised against a placebo.Randomised controlled trials , the strongest kind of study
  5. 17 read in full so far.Every number checked against the paper

Bar lengths use a square-root scale so the small numbers stay visible.

At a glance

How much research there is

  • 135 studies giving L-tyrosine to people
  • 61 of them randomised against a placebo
  • 1,824 people taking part, where studies say
  • 38 systematic reviews pooling the trials

Studies in people, by year published

L-tyrosine or NALT on its own.

Randomised, placebo-controlled Other designs
What was measured

What the studies looked at

Each study can measure several things. Choose a topic to see its studies in the list below.

Studies in people with a diagnosed condition are counted here and listed with their population. We describe what they measured, not what they might treat. Most studies also report safety; see below.

Doses and extracts

What was tested, and how much

L-tyrosine is a single compound, so milligrams compare directly. But most studies gave one dose sized to body weight, often 100 to 150 mg per kg (about 7 to 10 g for a 70 kg adult), and only studies with a set daily dose appear on this chart. Supplements also sell it as N-acetyl-L-tyrosine (NALT). The few studies of NALT in people gave it by drip, and much of it passed out unchanged in urine.

Daily amount, one dot per study

Summary readRead in full109 studies don't give a daily amount in their summary and aren't shown.

Studies per extract

  • N-acetyl-L-tyrosine5
  • Other named0
  • Not named130

Named extracts are the maker's brand. "Not named" means the study didn't say.

Have a label to check? Work out the L-tyrosine in your own label

Every study

All studies in people

Filter the list, then open a study on PubMed. A result shows once we've read the full paper. Older studies with no summary online were sorted from the title.

Study Who took part People Extract and daily dose LengthResult
Lin 2026Single-arm or open-labelHealthy adults48Not named–Not read in full yet
Matsumoto 2026Crossover, placeboHealthy community-dwelling men aged 20-60 years (mean age 43.4, BMI 23.2) recruited in Osaka, without chronic disease, thyroid disorders or MAOI use30Not named, 1,000 or 2,000 or 3,000 or 4,000 mg4 weeksUnclear
Bilgin 2026Crossover, placeboProfessional male football players aged 18-30 (mean 24.2 years) from the Turkish third tier (TFF 3. Lig), tested after a Wingate fatigue protocol24Not named–Unclear
Solon-Júnior 2026Crossover, placeboRecreationally trained male cyclists (level 3; mean age 32 years) cycling to exhaustion after a 60-min Stroop task to induce mental fatigue14Not named–Positive result
Averdunk 2026Single-arm or open-labelChildren with YARS1 deficiency9Not named–Not read in full yet
Donnan 2025Crossover, placeboWell-trained male student soccer players (mean age 19.75 years) exercising in heat (32 C, 50% rh)8Not named–No difference
McAllister 2024RCT, placeboHealthy young adults, mental stress challenge80Not named, 2,000 mg–Not read in full yet
Hart 2024RCT, placeboAdolescents aged 12-17 years with anorexia nervosa (DSM-IV; <85%, later <95%, weight for height) in inpatient and community child and adolescent mental health services; 6 girls and 1 boy randomised7Not named, 5,000 mg12 weeksUnclear
Mathar 2022Crossover, placeboHealthy right-handed non-smoking men without psychiatric or neurological illness, medication or drug use30Not named, 2,000 mg–Mixed results
Lim 2021RCT, placeboHealthy university students (mean age 22.8 years; 32 women, 16 men) without cardiac, hepatic, renal, neurological or psychiatric illness, addiction, or previous tyrosine or GABA supplement use48Not named, 2,000 mg–No difference
Hart 2021PharmacokineticAdolescents with anorexia nervosa and healthy peers4Not named12 weeksNot read in full yet
Robson 2020RCT, placeboHealthy university students (mean age 19.9; 59 women, 11 men)70Not named, 2,000 mg–Harm reported
Jongkees 2020Crossover, placeboHealthy young adults aged 18-30 (25 of 45 women, all using hormonal contraception)45Not named, 2,000 mg–No difference
Ahrens 2020RCT, placeboHealthy non-smoking adults aged 18-35 (analysed mean age about 24)45Not named, 2,000 mg–Mixed results
Froböse 2020Crossover, placeboHealthy right-handed older adults (inclusion 60-75; completers aged 61-71, mean 66.7; 16 men)33Not named–No difference
Lang 2020Crossover, placeboHealthy young and older adults, cold exposure18Not named–Not read in full yet
Tumilty 2020Crossover, placeboRecreationally trained men, warm environment8Not named–Not read in full yet
Soranzo 2019RCT, placeboHealthy university students (analysed sample mean age 20.4; 25 women, 21 men)56Not named, 2,000 mg–Unclear
Dennison 2019Crossover, placeboHealthy university students (mean age 20.8; 15 women, 9 men)24Not named, 2,000 mg–Mixed results
Bloemendaal 2018Crossover, placeboHealthy older adults (inclusion 60-75; analysed sample aged 61-72, mean 67.5; 15 men, 9 women)33Not named–No difference
Stock 2018Crossover, placeboYoung healthy adults26Not named–Not read in full yet
Lang 2017Crossover, placeboHealthy young and older adults, cold exposure22Not named–Not read in full yet
Israely 2017Crossover, placeboHospitalised women with chronic anorexia nervosa19Not named3 weeksNot read in full yet
Coull 2016RCT, placeboHealthy adults in heat stress21Not named–Not read in full yet
Colzato 2016RCT, placeboHealthy adults by DRD2 genotype–Not named–Not read in full yet
Lieberman 2015RCT, placeboHealthy US Navy and Marine personnel (72 men, 6 women, mean age 25) in the mock-captivity phase of Survival, Evasion, Resistance, and Escape (SERE) School, including two mock interrogations78Not named–Harm reported
Steenbergen 2015RCT, placeboHealthy adults22Not named–Not read in full yet
Coull 2015Crossover, placeboMale soccer players8Not named–Not read in full yet
Colzato 2015RCT, placeboHealthy adults, creativity tasks–Not named–Not read in full yet
DiFrancisco-Donoghue 2014RCT, placeboAdults aged 45-79 with Parkinson's disease taking L-dopa and diagnosed with orthostatic hypotension40Not named, 1,000 mg1 weeksNo difference
Dowlati 2014RCT, placeboHealthy breastfeeding women24Not named, 10,000 mg–Not read in full yet
Tumilty 2014Crossover, placeboEndurance-trained men, exercise in heat7Not named–Not read in full yet
Colzato 2014Crossover, placeboHealthy adults–Not named–Not read in full yet
Jongkees 2014OtherHealthy adults–Not named–Not read in full yet
Kishore 2013Crossover, placeboHealthy young men, heat exposure10Not named, 6,500 mg–Not read in full yet
Colzato 2013OtherHealthy adults–Not named–Not read in full yet
Watson 2012Crossover, placeboHealthy young men, exercise in heat8Not named–Not read in full yet
Tumilty 2011Crossover, placeboHealthy trained men, heat exercise8Not named–Not read in full yet
Lang 2010OtherYoung and older healthy adults20Not named–Not read in full yet
Badaloo 2010OtherChildren recovering from severe undernutrition13Not named–Not read in full yet
Belza 2009Crossover, placeboHealthy normal-weight men12Not named, 400 mg–Not read in full yet
Rafii 2008OtherHealthy adult men on controlled diet6Not named–Not read in full yet
Palinkas 2007RCT, placeboHealthy adults living in Antarctica43Not named, 12,000 mg20 weeksNot read in full yet
Mahoney 2007Crossover, placeboHealthy male and female military research volunteers aged 18-35 (mean age 20.5) exposed to repeated cold-water immersion19Not named–Mixed results
O'Brien 2007Crossover, placeboHealthy subjects in cold water15Not named–Not read in full yet
Sutton 2005Crossover, placeboHealthy men in load-carriage test20Not named–Not read in full yet
Waters 2003RCT, placeboHealthy young men, sleep-deprived76Not named–Not read in full yet
Hoffer 2003OtherAdults on parenteral nutrition13N-acetyl-L-tyrosine–Not read in full yet
Magill 2003RCT, placeboHealthy young men, sleep-deprived–Not named–Not read in full yet
Cui 2003OtherYouths exercising at 3700 m altitude–Not named–Not read in full yet
Chinevere 2002Crossover, placeboCompetitive male cyclists9Not named–Not read in full yet
Kalsner 2001PharmacokineticPeople with phenylketonuria on diet10Not named–Not read in full yet
Roberts 2001OtherHealthy men6Not named–Not read in full yet
Thorpe 2000OtherHealthy men–Not named–Not read in full yet
Deijen 1999RCT, active or other controlMilitary cadets in combat training21Not named–Not read in full yet
Thomas 1999Crossover, placeboHealthy men and women20Not named–Not read in full yet
Wiesel 1999Non-randomised controlledPatients with schizophrenia and healthy controls10Not named–Not read in full yet
Smith 1998Crossover, placeboPeople with phenylketonuria aged 6-2821Not named4 weeksNot read in full yet
Strüder 1998Crossover, placeboHealthy trained male cyclists10Not named, 20,000 mg–Not read in full yet
Lines 1997OtherPeople with phenylketonuria–Not named–Not read in full yet
Galloway 1996Single-arm or open-labelCocaine-dependent outpatients49Not named, 6,000 mg13 weeksNot read in full yet
Pietz 1995Crossover, placeboAdults with phenylketonuria24Not named4 weeksNot read in full yet
Dollins 1995Crossover, placeboHealthy adults, lower body negative pressure20Not named–Not read in full yet
Druml 1995PharmacokineticHepatic failure patients and healthy adults13N-acetyl-L-tyrosine–Not read in full yet
Neri 1995RCT, placeboHealthy adults, one night without sleep–Not named–Not read in full yet
Deijen 1994Crossover, placeboHealthy young adults under noise stress16Not named–Not read in full yet
Shurtleff 1994Crossover, placeboHealthy men, cold exposure8Not named–Not read in full yet
Clayton 1994Crossover, placeboHealthy male volunteers given ethanol–Not named–Not read in full yet
Deutsch 1994Crossover, placeboSchizophrenia inpatients on molindone–Not named, 10,000 mg3 weeksNot read in full yet
Christensen 1993PharmacokineticInfants on pediatric amino acid solution–N-acetyl-L-tyrosine–Not read in full yet
Wässer 1992Crossover, placeboChildren with phenylketonuria8Not named13 weeksNot read in full yet
Mazzocco 1992OtherSchool-aged children with phenylketonuria–Not named–Not read in full yet
Druml 1991PharmacokineticHemodialysis patients and healthy controls15N-acetyl-L-tyrosine–Not read in full yet
Gelenberg 1990RCT, placeboOutpatients with major depression65Not named4 weeksNot read in full yet
Magnusson 1989OtherHealthy volunteers11N-acetyl-L-tyrosine, 5,000 mg–Not read in full yet
Lemoine 1989Single-arm or open-labelParkinson's disease patients10Not named156 weeksNot read in full yet
Elwes 1989Crossover, placeboPeople with narcolepsy and cataplexy10Not named, 9,000 mg4 weeksNot read in full yet
Dissing 1989Single-arm or open-labelParkinson's disease patients5Not named, 15,000 mg7 weeksNot read in full yet
Carlson 1989OtherNormal subjects–Not named–Not read in full yet
Banderet 1989Crossover, placeboHealthy volunteers exposed to cold and hypoxia–Not named–Not read in full yet
Mouret 1988Single-arm or open-labelPatients with dopamine-dependent depression12Not named, 3,200 mg–Not read in full yet
Mouret 1988Single-arm or open-labelNarcolepsy patients8Not named26 weeksNot read in full yet
Al-Damluji 1988Crossover, placeboHealthy men8Not named–Not read in full yet
Eisenberg 1988Single-arm or open-labelChildren with ADHD7Not named–Not read in full yet
Lou 1987Non-randomised controlledPhenylketonuria patients aged 15-2414Not named–Not read in full yet
Reimherr 1987Single-arm or open-labelAdults with attention deficit disorder12Not named8 weeksNot read in full yet
Kondo 1987Single-arm or open-labelJuvenile parkinsonism patients and relatives–Not named–Not read in full yet
Wernze 1986Non-randomised controlledCirrhosis patients and healthy controls28Not named, 14,000 mg0 weeksNot read in full yet
Lieberman 1985Crossover, placeboHealthy young men20Not named–Not read in full yet
Cuche 1985OtherHealthy men15Not named–Not read in full yet
Sole 1985Crossover, placeboAdults with mild essential hypertension13Not named, 7,500 mg2 weeksNot read in full yet
Kvittingen 1985OtherTwo healthy adults with low enzyme activity2Not named–Not read in full yet
Ni 1985OtherAdult men–Not named–Not read in full yet
Raw 1984Non-randomised controlledCongenital pain insensitivity patients and controls–Not named–Not read in full yet
Lieberman 1984RCT, placeboUnclear–Not named–Not read in full yet
Johnston 1983Non-randomised controlledNormal-weight and obese women21Not named1 weeksNot read in full yet
Ishizuka 1983OtherHealthy men7Not named–Not read in full yet
Benedict 1983RCT, active or other controlHealthy male volunteers–Not named, 7,500 mg–Not read in full yet
Yamaguchi 1983Non-randomised controlledParkinson's disease patients and healthy controls–Not named–Not read in full yet
Rasmussen 1983RCT, placeboHealthy fasted men–Not named–Not read in full yet
Leathwood 1982Crossover, placeboHealthy volunteers60Not named, 500 mg–Not read in full yet
Growdon 1982Single-arm or open-labelParkinson's disease patients23Not named–Not read in full yet
Alonso 1982Non-randomised controlledHuman volunteers–Not named–Not read in full yet
Agharanya 1981Single-arm or open-labelHealthy volunteers11Not named0 weeksNot read in full yet
Antener 1981Non-randomised controlledMalnourished young mothers and healthy controls–Not named–Not read in full yet
Melamed 1980Single-arm or open-labelHealthy volunteers11Not named0 weeksNot read in full yet
Hoskins 1980OtherDepression patients–Not named–Not read in full yet
Gelenberg 1980OtherDepression patients–Not named–Not read in full yet
Nordlinger 1979Non-randomised controlledCirrhotic patients and controls26Not named–Not read in full yet
Glaeser 1979PharmacokineticHuman volunteers–Not named–Not read in full yet
Zinsser 1973OtherHumans, oxalate excretion–Not named–Not read in full yet
Tarlow 1972PharmacokineticChild with Hartnup variant and coeliac disease1Not named–Not read in full yet
Barrera 1971OtherHumans, taste threshold test–Not named–Not read in full yet
Williams 1971OtherThyroid disease patients–Not named–Not read in full yet
Cavagnini 1970OtherHumans, plasma insulin–Not named–Not read in full yet
Calne 1970OtherHumans, sympathetic nerve function–Not named–Not read in full yet
Modignani 1970OtherHyperthyroid patients–Not named–Not read in full yet
Braham 1969Non-randomised controlledParkinson's disease patients and controls–Not named–Not read in full yet
Fox 1968OtherThyroid disease patients–Not named–Not read in full yet
Besser 1968OtherThyroid disease patients–Not named–Not read in full yet
Lotti 1968Non-randomised controlledThyroid disease patients and normal subjects–Not named–Not read in full yet
Levine 1967Non-randomised controlledLiver disease patients and normal subjects–Not named–Not read in full yet
Farran 1966OtherThyrotoxicosis patients–Not named–Not read in full yet
Kalliomäki 1966OtherRheumatoid arthritis patients–Not named–Not read in full yet
RIVLIN 1965OtherThyrotoxicosis and myxedema patients–Not named–Not read in full yet
Tolbert 1963OtherWomen on minimal tyrosine diet–Not named–Not read in full yet
VARTIAINEN 1962Non-randomised controlledPatients with Addison's disease–Not named–Not read in full yet
HUANG 1961PharmacokineticHuman subjects–Not named–Not read in full yet
LEVERTON 1956OtherYoung women–Not named–Not read in full yet
ROSE 1955OtherAdult volunteers–Not named–Not read in full yet
SPICKARD 1954OtherAllergic patients–Not named–Not read in full yet
VARTIANINEN 1953OtherHuman subjects–Not named–Not read in full yet
FERRERO 1950OtherChronic polyarthritis patients–Not named–Not read in full yet
WOOLF 1950OtherPremature infants–Not named–Not read in full yet
CARRIE 1950PharmacokineticHuman subjects–Not named–Not read in full yet
Safety

What's known about safety

  • In trials

    In a 4-week trial of up to 4 g a day in 30 healthy men, side effects were no more common than with placebo. Nearly every other study gave a single dose, so long-term use is little studied.

    Matsumoto 2026, 4-week trial at 1 to 4 g a day; Hase 2015, review of 15 studies, all but one a single dose

  • In the UK

    Amino acids such as L-tyrosine can be used in food supplements. We found no official UK or EU upper limit. Norway's food safety committee judged 1,250 to 2,000 mg a day from supplements may carry a risk, based on a rat study, as long-term studies in people were lacking.

    FSA food supplements guidance; EU Novel Food Status Catalogue, no entry for tyrosine or NALT; VKM 2016, Norway; searches of FSA and EFSA, Oct 2026

  • Check first

    It isn't known whether it's safe in pregnancy or breastfeeding, it hasn't been studied for safety in healthy children, and how it mixes with medicines isn't well studied. Speak to a pharmacist or doctor first if any of these applies to you.

    VKM 2016, Norway, no data in pregnancy, breastfeeding or children; no UK guidance found, Oct 2026

How we built this

Where these studies come from

We list every published study of L-tyrosine and NALT in people. Trials that are free online are read in full; the rest are listed from their summaries.

  1. We search

    PubMed, the world's main library of medical research, for every paper on L-tyrosine.

  2. We keep studies in people

    Lab and animal work is counted but left out of the list, because it doesn't tell you what happens in people.

  3. We note the basics

    Who took part, how many, how much and for how long, from each study's published summary, or from the full paper once we've read it. A second check corrects what the first read gets wrong.

  4. We read them in full

    Results appear once we've read the whole paper and checked every number. The date at the top shows when this entry was last updated.

Download the study list

Every study in people as a spreadsheet, 135 rows, free to reuse with a link back.

Download the CSV

Versions

Each update to the data gets a new version number, so you can tell what changed and when.

See every version

1.4 · 8 Nov 2026. The result for one study shows again after a recheck found its paper's slip doesn't change it.

1.3 · 8 Nov 2026. Results for three studies with contradicting numbers now show Unclear.

1.2 · 7 Nov 2026. 17 studies read in full. One removed after a recheck.

1.1 · 3 Nov 2026. Four removed after a recheck.

1.0 · 19 Oct 2026. First release. Every published study giving L-tyrosine on its own to people is listed from its summary. None is read in full yet.